The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | CLL resistance mechanisms in the era of novel agents
Marek Mráz, PhD, Central European Institute of Technology, Brno, Czech Republic, discusses the resistance mechanisms which may lead to resistance of chronic lymphocytic leukemia (CLL) to treatment with novel agents, such as BTK inhibitors. Although resistance may be mediated by mutations in drug targets, it may also arise through mutations downstream to the drug targets or non-mutational non-genetic adaptation mechanisms. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
